CPhI South East Asia’s (March 12-14, 2019) first visit to the fast-growing pharma economy of Thailand “could not come at a better moment”, the event’s organizers report. Thailand is experiencing a boom amongst pharma manufacturers and rising demand for contract services, with multinational corporations increasingly looking for local partners to expedite market access into the wider region. Over the next five years, the pharma industry in Thailand is anticipated to grow by CAGR of 7% and reach THB 275bn by 2026. Growth is being driven by healthcare and pharmaceutical reforms, designed to increase access to high-value medicines, which is sustaining imports from both the United States and Europe. Meanwhile, generic medicines demand both regionally and international is resulting in robust exports growth. Emphasizing the interest from international pharma markets, pre-registration figures for the CPhI event have “more than tripled ahead of what will be the 8th edition in this fast-emerging pharma hub”. The show floor itself has grown by over 50% year-on-year, the organizers report, “further highlighting the renewed confidence amongst exhibitors in South East Asia”. Beyond the exhibition, the CPhI South East Asia Conference brings together the main regional pharmaceutical associations and regulators to help accelerate integration and partnerships. The conference is an opportunity to hear the most cutting-edge insights, learn new trends and exchange ideas. Key sessions will explore the ‘ASEAN Regulatory Framework’ and ‘FDA Framework and the requirements for importing APIs to Thailand by the FDA and the Ministry of Public Health’. Another highlight is the Exhibitor Seminars, which feature in-depth sessions on new products and innovations, as well as informative content from heavyweight knowledge partners: Clarivate Analytics, IQVIA and Affygility. The business matchmaking service will also once again be available to attendees – serving as an online tool to arrange meetings before the event, ensuring attendees maximise their time onsite. https://www.cphi.com/sea/
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.